…
Nika Pharmaceuticals, Inc. engages in the development and distribution pharmaceutical products for dietary supplements and antiviral drugs in the United States. The company offers ITV-1, TNG, physiolong, carotilen, fructin, dry boza, anthocylen C, hypocholestin, biodetoxin, silymaron, and solamentum products. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika Pharmaceuticals, Inc. in May 2022. Nika Pharmaceuticals, Inc. was incorporated in 2000 and is based in Henderson, Nevada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -0.08M | -0.10M | -0.06M | -3.18M | -0.01M |
| Net income | -0.08M | -0.10M | -0.06M | -3.18M | -0.01M |
| Selling general administrative | 0.08M | 0.10M | 0.06M | 0.18M | 0.01M |
| Selling and marketing expenses | - | - | - | 0.11M | 0.23M |
| Gross profit | - | - | - | - | 0.09M |
| Ebit | - | - | -0.13M | -3.25M | -0.17M |
| Ebitda | -0.08M | -0.10M | -0.06M | -3.18M | -0.01M |
| Depreciation and amortization | - | - | 0.06M | 3.18M | 0.01M |
| Operating income | -0.08M | -0.10M | -0.06M | -3.18M | -0.01M |
| Other operating expenses | 0.08M | 0.10M | 0.06M | 3.18M | 0.01M |
| Interest expense | - | - | - | - | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Income tax expense | - | - | -0.06M | -3.18M | -0.01M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.09M |
| Total operating expenses | 0.08M | 0.10M | 0.06M | 3.18M | 0.01M |
| Total other income expense net | - | - | - | 0.00M | -0.15M |
| Net income from continuing ops | -0.08M | -0.10M | -0.06M | -3.18M | -0.01M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 0.02M | 0.02M | 0.02M | 0.00M | 0.00M |
| Intangible assets | - | - | - | - | 0.65M |
| Other current assets | 0.02M | 0.02M | - | - | - |
| Total liab | 0.32M | 0.24M | 0.10M | 0.02M | 0.02M |
| Total stockholder equity | -0.30M | -0.22M | -0.08M | -0.02M | -0.02M |
| Other current liab | 0.32M | 0.48M | 0.10M | 0.02M | 0.16M |
| Common stock | 0.10M | 0.10M | 0.09M | 0.09M | 0.04M |
| Capital stock | 0.11M | 0.10M | 0.09M | 0.09M | 0.04M |
| Retained earnings | -9.00M | -8.93M | -3.40M | -3.34M | -0.15M |
| Good will | - | - | - | - | 0.65M |
| Cash | 0.00M | 0.00M | 0.02M | 0.00M | 0.00M |
| Total current liabilities | 0.32M | 0.24M | 0.10M | 0.02M | 0.01M |
| Current deferred revenue | - | - | - | - | 0.00M |
| Net debt | -0.00M | 0.24M | 0.08M | 0.02M | 0.02M |
| Short term debt | - | 0.24M | 0.10M | 0.02M | 0.01M |
| Short long term debt | - | - | - | - | 0.01M |
| Short long term debt total | - | 0.24M | 0.10M | 0.02M | 0.02M |
| Other stockholder equity | 8.60M | 8.60M | 3.23M | 3.23M | 0.09M |
| Total current assets | 0.02M | 0.02M | 0.02M | 0.00M | 0.00M |
| Net receivables | - | - | - | - | 0.04M |
| Long term debt | - | - | - | - | 0.01M |
| Accounts payable | - | - | - | - | 0.04M |
| Accumulated other comprehensive income | - | - | 0.00M | - | 5.03M |
| Non currrent assets other | - | - | - | - | -0.64M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.65M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total cashflows from investing activities | - | - | - | - | -0.01M |
| Net borrowings | 0.08M | 0.14M | 0.08M | 0.02M | 0.01M |
| Total cash from financing activities | 0.08M | 0.14M | 0.08M | 0.03M | 0.01M |
| Net income | -0.08M | -0.10M | -0.06M | -3.18M | -0.01M |
| Change in cash | -0.00M | -0.02M | 0.02M | 0.00M | -0.00M |
| Begin period cash flow | 0.00M | 0.02M | 0.00M | 0.00M | 0.00M |
| End period cash flow | 0.00M | 0.00M | 0.02M | 0.00M | 0.00M |
| Total cash from operating activities | -0.08M | -0.15M | -0.06M | -0.03M | -0.01M |
| Issuance of capital stock | - | - | 0.00M | 0.01M | 0.00M |
| Other cashflows from investing activities | - | - | - | - | -0.01M |
| Other cashflows from financing activities | 0.08M | 0.14M | 0.08M | 0.03M | -0.01M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -0.00M | -0.02M | - | - | 0.10M |
| Stock based compensation | - | - | - | 3.15M | - |
| Other non cash items | -0.00M | -0.04M | - | 3.15M | - |
| Free cash flow | -0.08M | -0.14M | -0.06M | -0.03M | -0.01M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| NIKA Nika BioTechnology Inc |
- -% |
0.35 | - | - | 1000000.00 | - | 1000000.00 |
| MKKGY Merck KGaA ADR |
-0.74 2.19% |
33.06 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
170.05 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.34 1.66% |
21.18 | - | 10.96 | 0.01 | 1.20 | 2.94 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.72 | - | 10.66 | 0.01 | 1.16 | 2.94 |
Nika Pharmaceuticals, Inc. engages in the development and distribution pharmaceutical products for dietary supplements and antiviral drugs in the United States. The company offers ITV-1, TNG, physiolong, carotilen, fructin, dry boza, anthocylen C, hypocholestin, biodetoxin, silymaron, and solamentum products. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika Pharmaceuticals, Inc. in May 2022. Nika Pharmaceuticals, Inc. was incorporated in 2000 and is based in Henderson, Nevada.
2269 Merrimack Valley Avenue, Henderson, NV, United States, 89044
702 326 3615
| Name | Title | Year Born |
|---|---|---|
| Mr. Scott Rose | CFO & Exec. Director | NA |
| Mr. Alan Wilson | Exec. Officer & Director | NA |
| Ms. Patricia Margaret Wilson | Corp. Sec. | NA |
| Mr. James W. McLeod P. Geo. | Consultant | 1943 |
| Mr. Dimitar Slavchev Savov | President, CEO, CFO & Director | 1958 |
| Mr. Clifford Redekop | Secretary & Director | 1949 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.